DK1741447T3 - Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler - Google Patents

Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler

Info

Publication number: DK1741447T3
Authority: DK; Denmark
Prior art keywords: inhibitors; insulin; glucose; fructose; nvp
Prior art date: 2000-01-21

Application number

DK06121896.2T

Other languages

English (en)

Inventor

Boerk Balkan

Thomas Edward Hughes

David Grenville Holmes

Edwin Bernard Villhauer

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-21

Filing date

2001-01-19

Publication date

2013-12-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27049636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1741447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-19 Application filed by Novartis Ag filed Critical Novartis Ag

2013-12-09 Application granted granted Critical

2013-12-09 Publication of DK1741447T3 publication Critical patent/DK1741447T3/da

Links

239000003472 antidiabetic agent Substances 0.000 title abstract 2
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title 1
229940125708 antidiabetic agent Drugs 0.000 title 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
208000002705 Glucose Intolerance Diseases 0.000 abstract 2
102000003638 Glucose-6-Phosphatase Human genes 0.000 abstract 2
108010086800 Glucose-6-Phosphatase Proteins 0.000 abstract 2
102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 2
108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 2
102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 abstract 2
101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
201000009104 prediabetes syndrome Diseases 0.000 abstract 2
108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 2
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 2
VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 abstract 1
208000010444 Acidosis Diseases 0.000 abstract 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
102000027487 Fructose-Bisphosphatase Human genes 0.000 abstract 1
108010017464 Fructose-Bisphosphatase Proteins 0.000 abstract 1
229940122904 Glucagon receptor antagonist Drugs 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000007976 Ketosis Diseases 0.000 abstract 1
206010027417 Metabolic acidosis Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
239000000674 adrenergic antagonist Substances 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000030136 gastric emptying Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000009229 glucose formation Effects 0.000 abstract 1
230000002440 hepatic effect Effects 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
230000004140 ketosis Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229930029653 phosphoenolpyruvate Natural products 0.000 abstract 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
229960001254 vildagliptin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK06121896.2T 2000-01-21 2001-01-19 Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler DK1741447T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48923400A	2000-01-21	2000-01-21
US61926200A	2000-07-19	2000-07-19
EP01909661A EP1248604B2 (en)	2000-01-21	2001-01-19	Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Publications (1)

Publication Number	Publication Date
DK1741447T3 true DK1741447T3 (da)	2013-12-09

Family

ID=27049636

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
DK06121898.8T DK1743655T3 (da)	2000-01-21	2001-01-19	Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
DK06121896.2T DK1741447T3 (da)	2000-01-21	2001-01-19	Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
DK06121894.7T DK1741445T3 (da)	2000-01-21	2001-01-19	Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
DK01909661.9T DK1248604T4 (da)	2000-01-21	2001-01-19	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
DK06121895T DK1741446T3 (da)	2000-01-21	2001-01-19	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK06121898.8T DK1743655T3 (da)	2000-01-21	2001-01-19	Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK06121894.7T DK1741445T3 (da)	2000-01-21	2001-01-19	Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
DK01909661.9T DK1248604T4 (da)	2000-01-21	2001-01-19	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
DK06121895T DK1741446T3 (da)	2000-01-21	2001-01-19	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler

Country Status (17)

Country	Link
US (1)	US20030139434A1 (da)
EP (5)	EP1741447B1 (da)
JP (7)	JP2003520226A (da)
CN (3)	CN1977842A (da)
AT (2)	ATE385421T1 (da)
AU (1)	AU2001237321A1 (da)
BR (1)	BRPI0107715B8 (da)
CA (2)	CA2397554C (da)
CY (6)	CY1106303T1 (da)
DE (3)	DE122008000018I1 (da)
DK (5)	DK1743655T3 (da)
ES (5)	ES2487897T3 (da)
FR (1)	FR08C0017I2 (da)
LU (1)	LU91436I2 (da)
NL (1)	NL300346I1 (da)
PT (5)	PT1741447E (da)
WO (1)	WO2001052825A2 (da)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2684168B2 (ja)	1995-10-30	1997-12-03	トーワ株式会社	離型抵抗力測定方法及び測定装置
AU6452098A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
KR20070053264A (ko)	1998-09-09	2007-05-23	메타베이시스 테라퓨틱스, 인크.	신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족억제제
CA2344246A1 (en) *	1998-09-17	2000-03-23	Akesis Pharmaceuticals, Inc.	Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
ES2487897T3 (es) *	2000-01-21	2014-08-25	Novartis Ag	Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
DE60125734T2 (de)	2000-03-08	2007-10-25	Metabasis Therapeutics, Inc., La Jolla	Neue aryl fructose-1,6-bisphosphatase inhibitoren
US7078397B2 (en)	2000-06-19	2006-07-18	Smithkline Beecham Corporation	Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) *	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
RU2328308C2 (ru) *	2000-07-06	2008-07-10	Метабэйсис Терапьютикс, Инк.	Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
CN100525768C (zh) *	2000-10-23	2009-08-12	史密丝克莱恩比彻姆公司	新化合物
DE60223920T2 (de)	2001-06-27	2008-11-13	Smithkline Beecham Corp.	Pyrrolidine als dipeptidyl-peptidase-inhibitoren
EP1406873B1 (en)	2001-06-27	2007-09-26	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
ATE370943T1 (de)	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
NZ534757A (en)	2002-03-12	2006-07-28	Merck & Co Inc	Substituted amides
US7524885B2 (en) *	2002-04-01	2009-04-28	The Governors Of The University Of Alberta	Compounds that stimulate glucose utilization and methods of use
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
KR20050012771A (ko) *	2002-06-03	2005-02-02	노파르티스 아게	치환된 시아노피롤리딘의 용도 및 이들을 함유하는고지혈증 및 관련 질환의 치료를 위한 조합 제제
JP4233524B2 (ja) *	2002-08-21	2009-03-04	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造およびその薬理組成物としての使用
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7648957B2 (en) *	2002-09-04	2010-01-19	Dsm Ip Assets B.V.	Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
US20060094722A1 (en) *	2002-09-26	2006-05-04	Eisai Co., Ltd.	Combination drug
EP1572196B1 (en) *	2002-12-10	2008-08-13	Novartis AG	Combination of a dpp-iv inhibitor and a ppar-alpha compound
EP1608317B1 (en)	2003-03-25	2012-09-26	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
RU2005140949A (ru) *	2003-06-27	2007-08-10	Д-р Редди`с Ресерч Фаундэйшн (IN)	Композиции, включающие балаглитазон и дополнительные противодиабетические соединения
FR2858556B1 (fr) *	2003-08-06	2006-03-10	Galenix Innovations	Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US7790736B2 (en)	2003-08-13	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2007504213A (ja) *	2003-09-02	2007-03-01	プロシディオン・リミテッド	糖血症コントロールの処置のための併用療法
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US20070149451A1 (en) *	2003-11-17	2007-06-28	Holmes David G	Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
MXPA06005518A (es)	2003-11-17	2006-08-17	Novartis Ag	Uso de inhibidores de la dipeptidil peptidasa iv.
NZ578743A (en)	2004-01-20	2011-04-29	Novartis Ag	Direct compression formulation and process
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EA013427B1 (ru)	2004-03-15	2010-04-30	Такеда Фармасьютикал Компани Лимитед	Ингибиторы дипептидилпептидазы
JP2007261945A (ja) *	2004-04-07	2007-10-11	Taisho Pharmaceut Co Ltd	チアゾール誘導体
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
TWI354569B (en) *	2004-05-28	2011-12-21	Bristol Myers Squibb Co	Coated tablet formulation and method
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2005117861A1 (en) *	2004-06-04	2005-12-15	Novartis Ag	Use of organic compounds
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
AU2005267093B2 (en)	2004-07-23	2009-10-01	Nuada Llc	Peptidase inhibitors
WO2006022428A1 (ja) *	2004-08-26	2006-03-02	Takeda Pharmaceutical Company Limited	糖尿病治療剤
WO2006047248A1 (en) *	2004-10-25	2006-05-04	Novartis Ag	Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7872124B2 (en)	2004-12-21	2011-01-18	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN101332303B (zh) *	2005-01-10	2012-09-26	艾尼纳制药公司	用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
NZ562433A (en) *	2005-03-25	2010-12-24	Glaxo Group Ltd	Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives, and their precursors
UY29440A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
JP2008115080A (ja) *	2005-04-22	2008-05-22	Taisho Pharmaceutical Co Ltd	併用医薬
BRPI0608469A2 (pt)	2005-04-22	2010-01-05	Alantos Pharmaceuticals Holding Inc	inibidores de dipeptidil peptidase-iv
PL1894567T3 (pl) *	2005-06-03	2013-01-31	Mitsubishi Tanabe Pharma Corp	Środki farmaceutyczne do podawania skojarzonego oraz ich zastosowanie
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
MY152185A (en) *	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US20080207490A1 (en) *	2005-07-07	2008-08-28	Postech Foundation	Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications
AU2006268650A1 (en) *	2005-07-12	2007-01-18	Novartis Ag	Combination of a DPP-IV inhibitor and a cannabinoid CB1 receptor antagonist
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP5027137B2 (ja)	2005-09-14	2012-09-19	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤の投与
KR101368988B1 (ko)	2005-09-16	2014-02-28	다케다 야쿠힌 고교 가부시키가이샤	디펩티딜 펩티다제 억제제
JP5072848B2 (ja) *	2005-09-20	2012-11-14	ノバルティスアーゲー	低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
AU2006297444B2 (en) *	2005-09-29	2010-08-12	Novartis Ag	Formulation comprising metformin and vildagli ptin
TW200738266A (en) *	2005-09-29	2007-10-16	Sankyo Co	Pharmaceutical agent containing insulin resistance improving agent
CA2623826A1 (en) *	2005-09-30	2007-04-12	Novartis Ag	Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
CN101365476A (zh) *	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
US8414921B2 (en)	2005-12-16	2013-04-09	Merck Sharp & Dohme Corp.	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
NZ569661A (en) *	2005-12-28	2011-06-30	Takeda Pharmaceutical	Therapeutic agent for diabetes
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1971862B1 (en)	2006-04-11	2010-11-10	Arena Pharmaceuticals, Inc.	Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CN109503584A (zh)	2006-05-04	2019-03-22	勃林格殷格翰国际有限公司	多晶型
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN101616673A (zh) *	2006-09-13	2009-12-30	武田药品工业株式会社	2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JP2010043002A (ja) *	2006-11-27	2010-02-25	Ajinomoto Co Inc	糖尿病治療剤
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
DK2107905T3 (da)	2007-02-01	2011-01-31	Takeda Pharmaceutical	Fast sammensætning omfattende alogliptin og pioglitazon
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
PE20090938A1 (es)	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
KR101607081B1 (ko)	2008-05-14	2016-03-29	가부시키가이샤산와카가쿠켄큐쇼	디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010029089A2 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
AR074797A1 (es) *	2008-10-10	2011-02-16	Japan Tobacco Inc	Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2367554A4 (en)	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid reflux inhibitor for the treatment of obesity and diabetes
CA2744697C (en)	2008-11-26	2016-06-21	Satiogen Pharmaceuticals, Inc.	Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
WO2010071750A1 (en) *	2008-12-19	2010-06-24	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds
EP2382216A1 (en)	2008-12-23	2011-11-02	Boehringer Ingelheim International GmbH	Salt forms of organic compound
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CA2751834C (en)	2009-02-13	2018-07-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2525790B1 (en)	2009-10-21	2020-05-27	Agios Pharmaceuticals, Inc.	Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en)	2009-10-21	2011-04-28	Agios Pharmaceuticals, Inc.	Methods and compositions for cell-proliferation-related disorders
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011080276A1 (en)	2009-12-29	2011-07-07	Genfit	Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
JP2013523819A (ja)	2010-04-06	2013-06-17	アリーナファーマシューティカルズ，インコーポレイテッド	Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
EP3593802A3 (en)	2010-05-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN106975074A (zh)	2010-06-24	2017-07-25	勃林格殷格翰国际有限公司	糖尿病治疗
CN103539791B (zh)	2010-09-22	2017-01-11	艾尼纳制药公司	Gpr119 受体调节剂和对与其相关的障碍的治疗
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
ES2713566T3 (es)	2011-07-15	2019-05-22	Boehringer Ingelheim Int	Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20130109671A1 (en)	2011-10-28	2013-05-02	Lumena Pharmaceuticals, Inc.	Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases
SG10201903512SA (en)	2011-10-28	2019-05-30	Lumena Pharmaceuticals Inc	Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EA021236B1 (ru) *	2012-10-03	2015-05-29	Дафот Энтерпраизес Лимитед	Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
KR20180006881A (ko)	2015-03-09	2018-01-19	인테크린 테라퓨틱스, 아이엔씨.	비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
EP4233840A3 (en)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
WO2018187350A1 (en)	2017-04-03	2018-10-11	Coherus Biosciences Inc.	PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
JP2022548214A (ja)	2019-09-17	2022-11-17	ノバルティスアーゲー	ビルダグリプチンとメトホルミンとの組み合わせ療法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US489795A (en)		1893-01-10		Steadying device for portable engines
US988496A (en)	1910-09-19	1911-04-04	Henry Obermann	Ventilator.
US4062950A (en)	1973-09-22	1977-12-13	Bayer Aktiengesellschaft	Amino sugar derivatives
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
US4342771A (en) *	1981-01-02	1982-08-03	Pfizer Inc.	Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US5216167A (en) *	1983-12-30	1993-06-01	Dr. Karl Thomae Gmbh	Phenylacetic acid benzylamides
DE3347565A1 (de)	1983-12-30	1985-07-11	Thomae Gmbh Dr K	Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AR240698A1 (es)	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPS6354321A (ja)	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
WO1986007056A1 (en)	1985-05-21	1986-12-04	Pfizer Inc.	Hypoglycemic thiazolidinediones
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5071773A (en)	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
EP0842925A1 (en)	1987-09-04	1998-05-20	Beecham Group Plc	Substituted thiazolidinedione derivatives
US4981784A (en)	1987-12-02	1991-01-01	The Salk Institute For Biological Studies	Retinoic acid receptor method
WO1989008651A1 (en)	1988-03-08	1989-09-21	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
EP0497894A4 (en)	1989-10-25	1993-03-31	The Salk Institute For Biological Studies	Receptor infection assay
US4997948A (en)	1989-10-27	1991-03-05	American Home Products	5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
AU637446B2 (en)	1990-01-16	1993-05-27	Baylor College Of Medicine	Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
DK0512042T3 (da)	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
DE69116563T3 (de)	1990-09-21	2006-07-06	The Salk Institute For Biological Studies, La Jolla	Durch protoonkogenischen Proteinkomplex AP-1 kontrollierte Verfahren
ATE149483T1 (de)	1991-07-30	1997-03-15	Ajinomoto Kk	Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
US5866563A (en)	1991-09-30	1999-02-02	The University Of British Columbia	Vanadium compositions
EP1396541A3 (en)	1991-12-06	2004-11-24	The Salk Institute For Biological Studies	Multimeric forms of members of the steroid/thyroid superfamily of receptors
EP0617614B1 (en)	1991-12-18	1998-03-04	The Salk Institute For Biological Studies	Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
ATE256653T1 (de)	1992-04-22	2004-01-15	Ligand Pharm Inc	Verbindungen mit retinoid x receptorselektivität
DE69334150T2 (de)	1992-05-14	2008-03-13	Baylor College Of Medicine, Houston	Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US5466861A (en)	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
JP2845743B2 (ja)	1992-12-28	1999-01-13	三菱化学株式会社	新規なナフタレン誘導体
WO1994015901A1 (en)	1993-01-11	1994-07-21	Ligand Pharmaceuticals Inc.	Compounds having selectivity for retinoid x receptors
WO1995004036A1 (en)	1993-01-11	1995-02-09	Ligand Pharmaceuticals Inc.	Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
EP0678086B1 (en)	1993-01-11	1999-12-08	Ligand Pharmaceuticals, Inc.	Compounds having selectivity for retinoid x receptors
US5399586A (en)	1993-03-11	1995-03-21	Allergan, Inc.	Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
JPH08512197A (ja)	1993-04-07	1996-12-24	リガンド・ファーマシューティカルズ・インコーポレーテッド	受容体アゴニストのスクリーニング方法
US5506102A (en)	1993-10-28	1996-04-09	Ligand Pharmaceuticals Incorporated	Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
WO1995018380A1 (en)	1993-12-30	1995-07-06	The Salk Institute For Biological Studies	Novel uses for gal4-receptor constructs
US5705515A (en)	1994-04-26	1998-01-06	Merck & Co., Inc.	Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
DE4416433A1 (de)	1994-05-10	1995-11-16	Hoechst Ag	Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
US5488510A (en)	1994-07-26	1996-01-30	Lemay; Edward J.	Enhanced depth perception viewing device for television
JP2848964B2 (ja)	1994-08-10	1999-01-20	エフ・ホフマン−ラロシュアーゲー	レチノイン酸ｘ受容体リガンド
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ES2148593T3 (es)	1994-12-30	2000-10-16	Ligand Pharm Inc	Compuestos retinoides trienoicos novedosos y metodos.
EP0800504B1 (en)	1994-12-30	1999-12-01	Ligand Pharmaceuticals Incorporated	Tricyclic retinoids, methods for their production and use
CA2223625C (en)	1995-06-06	2003-06-03	Pfizer Inc.	Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2224062C (en)	1995-06-06	2001-09-04	Pfizer Limited	Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
WO1997016442A1 (en)	1995-10-31	1997-05-09	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1997031901A1 (en)	1996-02-29	1997-09-04	Mikael Bols	Hydroxyhexahydropyridazines
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP1019043A4 (en)	1996-05-07	2003-07-30	Univ Pennsylvania	INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE
AU712057B2 (en)	1996-06-07	1999-10-28	Merck & Co., Inc.	Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
EP0827746B1 (en)	1996-09-05	2002-04-03	Eli Lilly And Company	Carbazole analogues as selective beta3 adrenergic agonists
JP4010377B2 (ja)	1996-09-06	2007-11-21	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5776954A (en)	1996-10-30	1998-07-07	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
FR2755439B1 (fr)	1996-11-05	1998-12-24	Virbac Sa	Derives aryloxypropanolamines, leur procede de preparation et leurs applications
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US5880139A (en)	1996-11-20	1999-03-09	Merck & Co., Inc.	Triaryl substituted imidazoles as glucagon antagonists
CA2271941A1 (en)	1996-11-20	1998-05-28	Merck & Co., Inc.	Triaryl substituted imidazoles and methods of use
JP2001504490A (ja)	1996-11-20	2001-04-03	メルクエンドカンパニーインコーポレーテッド	トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法
JP2000514088A (ja)	1996-11-20	2000-10-24	メルクエンドカンパニーインコーポレーテッド	グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール
US5952322A (en)	1996-12-05	1999-09-14	Pfizer Inc.	Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
JP2001509166A (ja)	1997-01-28	2001-07-10	メルクエンドカンパニーインコーポレーテッド	糖尿病および肥満の治療のためのβ▲下３▼作動薬としてのチアゾールベンゼンスルホンアミド
EP0973778A1 (en)	1997-03-07	2000-01-26	Novo Nordisk A/S	4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
AU6452098A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en)	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DK0970095T3 (da)	1997-03-07	2004-03-08	Metabasis Therapeutics Inc	Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
BR9810378A (pt)	1997-07-01	2000-08-29	Novo Nordisk As	Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
GB9715298D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
US6169087B1 (en)	1997-09-23	2001-01-02	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (PTPases)
UA57811C2 (uk)	1997-11-21	2003-07-15	Пфайзер Продактс Інк.	Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
AU1617499A (en)	1997-12-05	1999-06-28	Eli Lilly And Company	Selective beta3 adrenergic agonists
EP2823812A1 (en) *	1998-02-02	2015-01-14	Trustees Of Tufts College	Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
AU2610299A (en)	1998-02-05	1999-08-23	Novo Nordisk A/S	Hydrazone derivatives
US5998463A (en)	1998-02-27	1999-12-07	Pfizer Inc	Glycogen phosphorylase inhibitors
WO1999046244A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999046267A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999046268A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
WO1999046236A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999046237A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases
EP1070084A4 (en)	1998-03-16	2001-09-12	Ontogen Corp	PIPERAZINE AS INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE)
WO1999008501A2 (en)	1998-04-23	1999-02-25	Dr. Reddy's Research Foundation	New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6331633B1 (en)	1998-05-08	2001-12-18	Calyx Therapeutics Inc.	Heterocyclic analogs of diphenylethylene compounds
EP1077968A1 (en)	1998-05-12	2001-02-28	American Home Products Corporation	Naphtho[2,3-b]heteroar-4-yl derivatives
CA2330557A1 (en)	1998-05-12	1999-11-18	Robert Emmett Mcdevitt	Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6057316A (en)	1998-05-12	2000-05-02	American Home Products Corporation	4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
US6001867A (en)	1998-05-12	1999-12-14	American Home Products Corporation	1-aryl-dibenzothiophenes
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
EP0978279A1 (en)	1998-08-07	2000-02-09	Pfizer Products Inc.	Inhibitors of human glycogen phosphorylase
AU5154699A (en)	1998-09-02	2000-03-27	Novo Nordisk A/S	4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
KR20070053264A (ko)	1998-09-09	2007-05-23	메타베이시스 테라퓨틱스, 인크.	신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족억제제
JP2002527419A (ja)	1998-10-08	2002-08-27	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB2351081A (en)	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6030837A (en)	1999-08-03	2000-02-29	Isis Pharmaceuticals Inc.	Antisense inhibition of PEPCK-mitochondrial expression
ES2487897T3 (es) *	2000-01-21	2014-08-25	Novartis Ag	Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
TW200303742A (en) †	2001-11-21	2003-09-16	Novartis Ag	Organic compounds

2001
- 2001-01-19 ES ES06121898.8T patent/ES2487897T3/es not_active Expired - Lifetime
- 2001-01-19 DE DE122008000018C patent/DE122008000018I1/de active Pending
- 2001-01-19 PT PT61218962T patent/PT1741447E/pt unknown
- 2001-01-19 CA CA002397554A patent/CA2397554C/en not_active Expired - Lifetime
- 2001-01-19 CA CA2673615A patent/CA2673615C/en not_active Expired - Lifetime
- 2001-01-19 WO PCT/EP2001/000590 patent/WO2001052825A2/en not_active Ceased
- 2001-01-19 US US10/181,169 patent/US20030139434A1/en not_active Abandoned
- 2001-01-19 DK DK06121898.8T patent/DK1743655T3/da active
- 2001-01-19 DK DK06121896.2T patent/DK1741447T3/da active
- 2001-01-19 BR BRPI0107715A patent/BRPI0107715B8/pt not_active IP Right Cessation
- 2001-01-19 AT AT06121895T patent/ATE385421T1/de active
- 2001-01-19 ES ES06121894T patent/ES2433476T3/es not_active Expired - Lifetime
- 2001-01-19 DK DK06121894.7T patent/DK1741445T3/da active
- 2001-01-19 AT AT01909661T patent/ATE346613T1/de active
- 2001-01-19 CN CNA2006101699199A patent/CN1977842A/zh active Pending
- 2001-01-19 EP EP06121896.2A patent/EP1741447B1/en not_active Expired - Lifetime
- 2001-01-19 DK DK01909661.9T patent/DK1248604T4/da active
- 2001-01-19 DE DE60124861T patent/DE60124861T2/de not_active Expired - Lifetime
- 2001-01-19 PT PT01909661T patent/PT1248604E/pt unknown
- 2001-01-19 ES ES06121895T patent/ES2301142T3/es not_active Expired - Lifetime
- 2001-01-19 CN CN01803953A patent/CN1400908A/zh active Pending
- 2001-01-19 PT PT61218947T patent/PT1741445E/pt unknown
- 2001-01-19 PT PT06121895T patent/PT1741446E/pt unknown
- 2001-01-19 DE DE60132723T patent/DE60132723T2/de not_active Expired - Lifetime
- 2001-01-19 EP EP06121898.8A patent/EP1743655B1/en not_active Expired - Lifetime
- 2001-01-19 EP EP01909661A patent/EP1248604B2/en not_active Expired - Lifetime
- 2001-01-19 AU AU2001237321A patent/AU2001237321A1/en not_active Abandoned
- 2001-01-19 CN CN2011102233943A patent/CN102327614A/zh active Pending
- 2001-01-19 PT PT61218988T patent/PT1743655E/pt unknown
- 2001-01-19 EP EP06121895A patent/EP1741446B1/en not_active Expired - Lifetime
- 2001-01-19 EP EP06121894.7A patent/EP1741445B1/en not_active Expired - Lifetime
- 2001-01-19 DK DK06121895T patent/DK1741446T3/da active
- 2001-01-19 JP JP2001552873A patent/JP2003520226A/ja active Pending
- 2001-01-19 ES ES06121896.2T patent/ES2436610T3/es not_active Expired - Lifetime
- 2001-01-19 ES ES01909661T patent/ES2275654T5/es not_active Expired - Lifetime
2006
- 2006-07-10 JP JP2006189416A patent/JP2006273873A/ja active Pending
- 2006-12-29 CY CY20061101859T patent/CY1106303T1/el unknown
2008
- 2008-04-24 CY CY20081100459T patent/CY1107423T1/el unknown
- 2008-05-09 LU LU91436C patent/LU91436I2/fr unknown
- 2008-05-12 CY CY200800010C patent/CY2008010I1/el unknown
- 2008-05-14 FR FR08C0017C patent/FR08C0017I2/fr active Active
- 2008-05-14 NL NL300346C patent/NL300346I1/nl unknown
2011
- 2011-03-02 JP JP2011045331A patent/JP5835910B2/ja not_active Expired - Lifetime
- 2011-03-30 JP JP2011076253A patent/JP5824224B2/ja not_active Expired - Lifetime
2013
- 2013-10-09 CY CY20131100877T patent/CY1114466T1/el unknown
- 2013-11-08 CY CY20131100996T patent/CY1114593T1/el unknown
2014
- 2014-02-06 JP JP2014020963A patent/JP6095589B2/ja not_active Expired - Lifetime
- 2014-08-08 CY CY20141100633T patent/CY1115449T1/el unknown
2015
- 2015-07-31 JP JP2015151372A patent/JP6104331B2/ja not_active Expired - Lifetime
2017
- 2017-01-19 JP JP2017007638A patent/JP6374995B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1977842A (zh)	2007-06-13
LU91436I2 (fr)	2008-07-09
CY1114466T1 (el)	2016-10-05
CA2397554C (en)	2009-09-22
ES2301142T3 (es)	2008-06-16
PT1741445E (pt)	2013-11-11
JP2015214572A (ja)	2015-12-03
AU2001237321A1 (en)	2001-07-31
US20030139434A1 (en)	2003-07-24
CA2397554A1 (en)	2001-07-26
DK1248604T4 (da)	2012-05-21
ES2275654T5 (es)	2012-06-07
JP6104331B2 (ja)	2017-03-29
CY2008010I2 (el)	2009-11-04
ES2433476T3 (es)	2013-12-11
EP1741447A3 (en)	2007-01-17
HK1102405A1 (en)	2007-11-23
BR0107715A (pt)	2002-11-19
WO2001052825A2 (en)	2001-07-26
ES2487897T3 (es)	2014-08-25
PT1743655E (pt)	2014-09-09
DE60124861D1 (de)	2007-01-11
JP6374995B2 (ja)	2018-08-15
CN102327614A (zh)	2012-01-25
JP2003520226A (ja)	2003-07-02
PT1741446E (pt)	2008-05-09
HK1102424A1 (en)	2007-11-23
JP2014088435A (ja)	2014-05-15
FR08C0017I2 (fr)	2010-12-31
EP1743655A1 (en)	2007-01-17
DE122008000018I1 (de)	2008-08-14
JP6095589B2 (ja)	2017-03-15
EP1741446A3 (en)	2007-01-17
EP1741446B1 (en)	2008-02-06
EP1741445B1 (en)	2013-08-14
EP1743655B1 (en)	2014-06-25
EP1248604B1 (en)	2006-11-29
EP1741447B1 (en)	2013-09-18
BRPI0107715B1 (pt)	2016-07-05
CN1400908A (zh)	2003-03-05
CY1106303T1 (el)	2011-10-12
DK1248604T3 (da)	2007-02-19
EP1741445A2 (en)	2007-01-10
LU91436I9 (da)	2019-01-02
CY1107423T1 (el)	2010-07-28
DE60132723T2 (de)	2009-01-29
ES2436610T3 (es)	2014-01-03
EP1248604A2 (en)	2002-10-16
ATE346613T1 (de)	2006-12-15
CA2673615C (en)	2013-07-16
WO2001052825A3 (en)	2002-03-28
BRPI0107715B8 (pt)	2021-05-25
CA2673615A1 (en)	2001-07-26
EP1741446A2 (en)	2007-01-10
DE60124861T2 (de)	2007-05-10
ES2275654T3 (es)	2007-06-16
JP5835910B2 (ja)	2015-12-24
DK1741445T3 (da)	2013-11-04
EP1741445A3 (en)	2007-01-24
HK1102422A1 (en)	2007-11-23
JP2011162550A (ja)	2011-08-25
HK1108359A1 (en)	2008-05-09
CY2008010I1 (el)	2009-11-04
CY1114593T1 (el)	2016-10-05
NL300346I1 (da)	2008-07-01
DE60132723D1 (de)	2008-03-20
DK1741446T3 (da)	2008-06-02
EP1741447A2 (en)	2007-01-10
PT1741447E (pt)	2013-12-11
JP2006273873A (ja)	2006-10-12
FR08C0017I1 (da)	2008-07-18
JP5824224B2 (ja)	2015-11-25
PT1248604E (pt)	2007-01-31
DK1743655T3 (da)	2014-08-18
ATE385421T1 (de)	2008-02-15
EP1248604B2 (en)	2012-02-29
JP2017081994A (ja)	2017-05-18
CY1115449T1 (el)	2017-01-04
JP2011116772A (ja)	2011-06-16

Publication	Publication Date	Title
DK1741447T3 (da)	2013-12-09	Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US7981918B2 (en)	2011-07-19	Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006070195A8 (en)	2006-08-24	Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
CA2432799A1 (en)	2002-06-27	Pyrazole compounds useful as protein kinase inhibitors
BR9714130A (pt)	2000-02-29	2-cianopirrolidinas n-substituìdas
BRPI0518409A2 (pt)	2008-11-18	combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina
WO2006039325A3 (en)	2007-01-04	Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2004018467A3 (de)	2004-05-13	Phenacylxanthinderivate als dpp-iv-hemmer
WO2006119260A3 (en)	2008-02-28	Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
WO2007027651A3 (en)	2007-05-31	Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
GR3034904T3 (en)	2001-02-28	Endothelin antagonists.
NO20065489L (no)	2006-11-28	Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer
WO2007014008A3 (en)	2007-07-12	Benzenesulfonamide inhibitor of ccr2 chemokine receptor
AU2003229548A1 (en)	2003-09-09	Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
WO2006084757A3 (en)	2006-11-23	Combination of ca/mg salt of valsartan with an antidiabetic agent
WO2002061083A1 (fr)	2002-08-08	Nouvelle proteine de recepteur couple aux proteines g et son adn
WO2005035722A3 (en)	2007-08-02	Variant polypeptides containing plekstrin homology domains and uses therefor